Concord Biotech Q1 Results FY26: Q1 PAT Falls 26.07% to ₹44.06 Crore; Revenue Down 5.47% YoY

Concord Biotech Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹203.99	₹215.80
Profit Before Tax (PBT)	₹75.08	₹91.59
Profit After Tax (PAT)	₹44.06	₹59.59

(Figures in crores)

Concord Biotech Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹203.99	₹215.80
Profit Before Tax (PBT)	₹75.08	₹91.59
Profit After Tax (PAT)	₹42.57	₹58.24

(Figures in crores)

Concord Biotech Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Concord Biotech clocked Q1 FY26 consolidated revenue of ₹203.99 crores vs ₹215.80 crores. 
• On the profit front, Concord Biotech earned a consolidated PAT of ₹44.06 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹59.59 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 26.07% YoY, and revenue fell  5.47% YoY. 
• As per the standalone figures, the quarterly PAT of Concord Biotech has decreased by 26.91%, and revenue has decreased by 5.47% YoY.

Concord Biotech Share Price Performance

On the opening bell of 11th August 2025, the shares of Concord Biotech opened at ₹1,485.80 per share. However, the initial gains are sustained as of now, and Concord Biotech shares are trading at ₹1,571.80 per share, higher than their opening price. 

Considering the long-term performance, Concord Biotech shares have yielded close to 4.00% returns in the past 1 year, and 5-year returns stand at 66.55%. Over the maximum timeframe, the Concord Biotech share provided 66.55% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Concord Biotech shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Aurobindo Pharma Q1 Results FY26: Q1 PAT Narrows 10.28% to ₹824.75 Crore; Revenue Surged 3.98% YoY

Recent Articles

Mahendra Realtors IPO GMP & Review: Apply or Avoid?

Regaal Resources IPO GMP & Review: Apply or Avoid?

Icodex Publishing Solutions IPO GMP & Review: Apply or Avoid?

Titan Q1 Results FY26: Q1 PAT Rises 52.59% to ₹1,091.00 Crore; Revenue Up 24.55% YoY

Kalyan Jewellers India Q1 Results FY26: Q1 PAT Rises 48.56% to ₹264.08 Crore; Revenue Up 31.49% YoY

Solar Industries Q1 Results FY26: Q1 PAT Rises 18.24% to ₹132.13 Crore; Revenue Up 27.88% YoY

NBCC India Q1 Results FY26: Q1 PAT Rises 26.29% to ₹132.13 Crore; Revenue Up 11.61% YoY